Selecting the appropriate anesthetic protocol for the individual animal is an essential part of laboratory animal experimentation. The present study compared the characteristics of four anesthetic protocols in mice, focusing on the vital signs. Thirty-two male ddY mice were divided into four groups and administered anesthesia as follows: pentobarbital sodium monoanaesthesia; ketamine and xylazine combined (K/X); medetomidine, midazolam, and butorphanol combined (M/M/B); and isoflurane. In each group, rectal temperature, heart rate, respiratory rate, and O2 saturation (SPO2) were measured, and the changes over time and instability in these signs were compared. The anesthetic depth was also evaluated in each mouse, and the percentage of mice achieving surgical anesthesia was calculated. K/X anesthesia caused remarkable bradycardia, while the respiratory rate and SPO2 were higher than with the others, suggesting a relatively strong cardiac influence and less respiratory depression. The M/M/B group showed a relatively lower heart rate and SPO2, but these abnormalities were rapidly reversed by atipamezole administration. The pentobarbital group showed a lower SPO2, and 62.5% of mice did not reach a surgical anesthetic depth. The isoflurane group showed a marked decrease in respiratory rate compared with the injectable anesthetic groups. However, it had the most stable SPO2 among the groups, suggesting a higher tidal volume. The isoflurane group also showed the highest heart rate during anesthesia. In conclusion, the present study showed the cardiorespiratory characteristics of various anesthetic protocols, providing basic information for selecting an appropriate anesthetic for individual animals during experimentation.
Selecting the appropriate anesthetic protocol for the individual animal is an essential part of laboratory animal experimentation. The present study compared the characteristics of four anesthetic protocols in mice, focusing on the vital signs. Thirty-two male ddY mice were divided into four groups and administered anesthesia as follows: pentobarbital sodium monoanaesthesia; ketamine and xylazine combined (K/X); medetomidine, midazolam, and butorphanol combined (M/M/B); and isoflurane. In each group, rectal temperature, heart rate, respiratory rate, and O2 saturation (SPO2) were measured, and the changes over time and instability in these signs were compared. The anesthetic depth was also evaluated in each mouse, and the percentage of mice achieving surgical anesthesia was calculated. K/X anesthesia caused remarkable bradycardia, while the respiratory rate and SPO2 were higher than with the others, suggesting a relatively strong cardiac influence and less respiratory depression. The M/M/B group showed a relatively lower heart rate and SPO2, but these abnormalities were rapidly reversed by atipamezole administration. The pentobarbital group showed a lower SPO2, and 62.5% of mice did not reach a surgical anesthetic depth. The isoflurane group showed a marked decrease in respiratory rate compared with the injectable anesthetic groups. However, it had the most stable SPO2 among the groups, suggesting a higher tidal volume. The isoflurane group also showed the highest heart rate during anesthesia. In conclusion, the present study showed the cardiorespiratory characteristics of various anesthetic protocols, providing basic information for selecting an appropriate anesthetic for individual animals during experimentation.
When following the basic principles of laboratory animal welfare, the selection of an
appropriate and effective anesthetic protocol for each individual animal is an essential
part of laboratory animal experimentation. Laboratory mice are anesthetized by either
inhalation of volatile anesthetics or injection of drugs. Injectable anesthesia is often
administered in rodents through the subcutaneous or intraperitoneal route. Injectable
anesthesia during rodent surgery can be achieved using a mixture of ketamine and sedatives
or using medetomidine-based balanced anesthesia [2,
16, 17].
Inhalant anesthetics available for use in laboratory animals include halothane, isoflurane,
sevoflurane, and desflurane [1, 10, 12]. Among them, isoflurane is
most the common inhalant anesthetic used in rodents [22]. Inhalant anesthesia is highly demanded in rodents because the anesthetic
depth can be easily controlled.Along with compliance with the principles of laboratory animal welfare, it is also
important to choose an appropriate anesthesia for experimental intervention because it can
influence the experimental data [10]. One factor in
selecting an anesthetic is the required level of anesthetic depth, that is, muscle
relaxation, analgesia, and hypnotic action, which varies depending on the surgical
procedure. Another important factor is the potential for adverse reactions. Administration
of anesthetic agents induces systemic effects on the neuronal, cardiorespiratory, metabolic,
and immune systems [4, 19, 29]. Among them, cardiovascular and
respiratory depression is a major adverse reaction. The particular cardiovascular
abnormalities vary among anesthetic protocols [4,
10]. Therefore, understanding the effect of
anesthesia on cardiorespiratory adverse reactions is important when selecting the anesthetic
for laboratory animal experimentation. Cardiovascular and respiratory function can be
assessed by monitoring vital signs, which include the heart rate, respiratory rate, blood
pressure, and O2 saturation (SPO2).Although mice have often been used in basic anesthesiology studies, the safety of mouse
anesthesia for experimental use has not been fully evaluated. The main purpose of the
present study was to compare the features of injectable and inhalant anesthetics in mice,
focusing on vital signs. Cardiorespiratory influence was evaluated for four anesthetic
protocols, including ketamine xylazine combined, medetomidine-based balanced anesthesia,
pentobarbital sodium monoanesthesia, and isoflurane. The variance in anesthetic depth for
each medication was also evaluated. The aim of the present study was to better understand
murine anesthesia.
Materials and Methods
Animals
Thirty-two male ddY mice aged 7 weeks and weighing 33.4–36.0 g were obtained from a
commercial vendor (SLC:ddY, Japan SLC Inc., Shizuoka, Japan). We selected ddY mice in the
present study, since they have been used in animal experimentation, including
pharmacological and toxicological trials. The animals were acclimated to the facility for
1 week before experimentation and kept in polycarbonate cages (CL-0106–1; 310 mm × 360 mm
× 175 mm; CLEA Japan Inc., Tokyo, Japan) with wood shavings. The animals were kept in a
room equipped with a barrier system at the Research Institute of Biosciences, Azabu
University. The room was air-conditioned at a temperature of 22 ± 1◦C and a
humidity of 55 ± 5% and was lit 14 h each day from 06:00 to 20:00. Mice were fed a
pelleted mouse diet (mouse and rat chow; MC-2, CLEA Japan, Tokyo, Japan)ad
libitum and had unrestricted access to sterilized drinking water provided in a
water bottle. All animals were examined and deemed clinically healthy before use in the
study. All experiments were conducted when the mice were 8 weeks of age. To minimize the
influence of the circadian rhythm, experiments and weighing procedures were performed
between 10:00 and 13:00. At the study conclusion, the subjects were euthanized by cervical
dislocation after intraperitoneal administration of pentobarbital sodium (Somnopentyl,
Kyoritsu Seiyaku Co., Ltd., Tokyo, Japan) at 100 mg/kg. All procedures in the present
study were in accordance with the guidelines approved by the Animal Research Committee of
Azabu University.
Anesthesia
The anesthetic, sedative, and analgesic agents used in the present study were as follows:
ketamine hydrochloride (Ketalar, Sankyo Lifetech Co., Ltd., Tokyo, Japan), xylazine
(Celactar, Bayer Yakuhin Ltd., Tokyo, Japan), pentobarbital sodium (Somnopentyl, Kyoritsu
Seiyaku Co., Ltd.), medetomidine hydrochloride (Domitol, Meiji Seika Pharma Co., Ltd.,
Tokyo, Japan), midazolam (Dormicum, Astellas Pharma Inc., Tokyo, Japan), butorphanol
(Vetorphale, Meiji Seika Pharma Co., Ltd.), and isoflurane (Isoflu, DS Pharma Animal
Health Co., Ltd., Osaka, Japan). All agents were kept at room temperature before use.
Animals were divided into four groups corresponding to each anesthetic protocol as
follows: ketamine hydrochloride and xylazine combined (K/X; ketamine hydrochloride 100
mg/kg and xylazine 10 mg/kg); pentobarbital monoanesthesia (50 mg/kg); medetomidine,
midazolam, and butorphanol combined (M/M/B; medetomidine 0.3 mg/kg, midazolam 4 mg/kg, and
butorphanol 5 mg/kg); and inhalant anesthesia using isoflurane (5% for induction and 2%
for maintenance). In the M/M/B group, mice were administered atipamezole (Antisedan,
Zoetis Japan Inc., Tokyo, Japan) at a dose of 0.3 mg/kg 30 min after the administration of
M/M/B. All injectable anesthetics were administered intraperitoneally. The dose and
concentration of each agent were as reported previously in mice [4, 5, 17]. Before administration, the concentration of M/M/B, K/X, and
pentobarbital sodium was adjusted to 6 ml/kg by diluting with saline. In the M/M/B
anesthetic group, a mixture of medetomidine, midazolam, and butorphanol with saline was
prepared and then concurrently administered. Similarly, the mixture of ketamine
hydrochloride and xylazine was adjusted with saline before concurrent administration.Isoflurane anesthesia was administered using a commercially available rodent inhalant
anesthesia apparatus (SomnoSuite Small Animal Anesthesia System, Kent Scientific
Corporation), which has a digital vaporizer and internal air-flow pump. The vaporized
anesthetic gas was introduced into the induction chamber and nose mask (Kent Scientific
Corporation) at a flow rate of 32 ml/min. The nose mask was covered with a latex membrane
that had a hole in the center to fit closely around the nose. Initially, mice were induced
with isoflurane at a 5% concentration. Once loss of the postural reaction and righting
reflex was confirmed, the mice were rapidly transferred to the nose mask, and anesthesia
was maintained with 2% isoflurane (Fig. 1).
Fig. 1.
Vital signs monitoring during isoflurane anesthesia in mice. The rectal probe and
pulse oximeter are located at the colorectum and tail base, respectively.
Vital signs monitoring during isoflurane anesthesia in mice. The rectal probe and
pulse oximeter are located at the colorectum and tail base, respectively.
Vital signs monitoring
Vital signs were measured before anesthesia and every 5 min during a 40 min period.
Rectal temperature, heart rate, respiratory rate, and SPO2 were evaluated in
each animal. Rectal temperature (°C) was measured using a commercial rectal temperature
sensor (Right Temp, Kent Scientific Corporation) inserted into the colorectum. The heart
rate (beats/min) and SPO2 (%) were assessed using a rodent pulse oximeter and
heart rate monitor (MouseSTAT, Kent Scientific Corporation), with the pulse oximeter
sensor attached to the tail base (Fig. 1). The
respiratory rate (breaths/min) was assessed by counting the number of thoracic movements
per min. To measure the baseline values, the mice were introduced into animal holders.
After beginning anesthesia, the mice were positioned on a nylon pad to maintain a
consistent surface temperature underneath them.Following vital signs monitoring, the trend in vital signs over time was compared between
each group. The instability of vital signs was analyzed using the coefficient of variance
(CV) in each individual mouse and the calculated mean CV per parameter in each group.
Assessment of anesthetic depth
Anesthetic depth in each group was assessed with noxious stimuli as previously reported
in mice [17]. Four reflexes were evaluated, the
pedal withdrawal reflex in the forelimbs and hind limbs, the tail pinch reflex, and the
eyelid reflex. Noxious stimuli were performed using atraumatic forceps. The anesthetic
depth score was determined based on the number of reflex reactions; if no reflexes to
stimuli were observed, the score was 4. Anesthetic depth was measured every 10 min for 30
min after administering the agents. Scores of 3 and 4 were defined as indicating a
surgical anesthetic depth.
Data analyses
A repeated measures ANOVA was used to analyze each vital sign value. When data were
significant, Dunnett’s multiple comparison method was performed to compare each parameter
between the baseline and other time points. The differences between the treatments at each
time point were analyzed using Tukey’s test. Instability of each vital sign in each group
was compared with ANOVA, followed by Tukey’s test. The rate mice reached a surgical
anesthetic depth in each group was compared using Fisher’s exact test. Data were expressed
as the mean ± SD. A P-value<0.05 was considered significant. All
analyses were performed using commercially available software (StatMate IV; ATMS Co.,
Ltd., Tokyo, Japan).
Results
During the study period, there were no fatal events, and anesthesia was induced in all
animals within 5 min; thus vital signs were measured beginning 5 min after drug
administration. Baseline differences between the groups in each parameter were not
statistically significant.The trend in rectal temperature over time is shown in Fig. 2. All groups showed a significant decrease in rectal temperature during the entire
anesthetic period. There was no significant difference between the groups. Next, pulse rate
was evaluated in each group. The results showed that a decreased heart rate was observed
beginning 5 min after drug administration in all groups (Fig. 3). When compared to the isoflurane and pentobarbital groups, the K/X and M/M/B groups
had significantly lower heart rates. In the M/M/B group, the heart rate was significantly
increased 5 min after administering atipamezole (373 ± 24 beats/min at 30 min, 491 ± 17
beats/min at 35 min). The heart rate decrease in the K/X group was time dependent, and the
heart rate did not recover during the study period.
Fig. 2.
Measured core body temperature over time during each anesthetic protocol. : Ketamine
and xylazine combined anesthesia (K/X, 80/8 mg/kg). : Medetomidine, midazolam, and
butorphanol combined anesthesia with atipamezole (M/M/B, 0.3/4.0/5.0 mg/kg;
atipamezole, 0.3 mg/kg). : Pentobarbital sodium (50 mg/kg). : Isoflurane (induction,
5%, maintenance, 2%). Data are represented as means ± SD of 8 mice. There were no
significant differences between the groups.
Fig. 3.
Measured heart rate (beats/min) over time. : Ketamine and xylazine combined
anesthesia (K/X, 80/8 mg/kg). : Medetomidine, midazolam, and butorphanol combined
anesthesia with atipamezole (M/M/B, 0.3/4.0/5.0 mg/kg; atipamezole, 0.3 mg/kg). :
Pentobarbital sodium (50 mg/kg). : Isoflurane (induction, 5%; maintenance, 2%). Data
are represented as means ± SD of 8 mice. There were significant differences between
the groups as follows: a, K/X and M/M/B groups; b, K/X and pentobarbital groups c, K/X
and isoflurane groups; d, M/M/B and pentobarbital groups; and e, M/M/B and isoflurane
groups.
Measured core body temperature over time during each anesthetic protocol. : Ketamine
and xylazine combined anesthesia (K/X, 80/8 mg/kg). : Medetomidine, midazolam, and
butorphanol combined anesthesia with atipamezole (M/M/B, 0.3/4.0/5.0 mg/kg;
atipamezole, 0.3 mg/kg). : Pentobarbital sodium (50 mg/kg). : Isoflurane (induction,
5%, maintenance, 2%). Data are represented as means ± SD of 8 mice. There were no
significant differences between the groups.Measured heart rate (beats/min) over time. : Ketamine and xylazine combined
anesthesia (K/X, 80/8 mg/kg). : Medetomidine, midazolam, and butorphanol combined
anesthesia with atipamezole (M/M/B, 0.3/4.0/5.0 mg/kg; atipamezole, 0.3 mg/kg). :
Pentobarbital sodium (50 mg/kg). : Isoflurane (induction, 5%; maintenance, 2%). Data
are represented as means ± SD of 8 mice. There were significant differences between
the groups as follows: a, K/X and M/M/B groups; b, K/X and pentobarbital groups c, K/X
and isoflurane groups; d, M/M/B and pentobarbital groups; and e, M/M/B and isoflurane
groups.To assess the influence of respiratory function, respiratory rate and SPO2 were
compared in each group. A decreased respiratory rate was observed in all groups during the
anesthetic period (Fig. 4). The decrease was marked in the isoflurane group, and the difference was significant
at 5–35 min compared with the injectable anesthesia groups. However, the respiratory rate
recovered in the isoflurane group 5 min after discontinuing inhalation (78 ± 19 breaths/min
at 35 min, 150 ± 49 breaths/min at 40 min, P<0.05). The course of
SPO2 over time in each group is shown in Fig. 5. Each anesthetic group showed a significant decrease in SPO2 after
initiation of anesthesia. In the M/M/B, pentobarbital, and isoflurane groups, the
SPO2 was significantly decreased at 5–35 min compared with baseline. In the
M/M/B group, a significant increase of SPO2 value was observed 10 min after the
administration of atipamezole (87.8 ± 1.6% at 30 min, 95.7 ± 1.2% at 40 min,
P<0.05). The K/X group showed a significant SPO2 decrease
only at 35–40 min after anesthesia (98.9% ± 0.1% at baseline, 91.0% ± 1.6% at 35 min, 95% ±
1.3% at 40 min, P<0.05). Compared with the other injectable anesthetic
groups, the K/X group showed significantly high SPO2 values. The M/M/B group
showed lower SPO2 values compared with those of the isoflurane group.
Fig. 4.
Measured respiratory rate (breaths/min) over time. : Ketamine and xylazine combined
anesthesia (K/X: 80/8 mg/kg). : Medetomidine, midazolam, and butorphanol combined
anesthesia with atipamezole (M/M/B: 0.3/4.0/5.0 mg/kg, atipamezole: 0.3 mg/kg). :
Pentobarbital sodium (50 mg/kg). : Isoflurane (induction,5%; maintenance, 2%). Data
are represented as means ± SD of 8 mice. There were significant differences between
the groups as follows: a, K/X and M/M/B groups; c, K/X and isoflurane groups; d, M/M/B
and pentobarbital groups; and e, M/M/B and isoflurane groups; and f, pentobarbital and
isoflurane groups.
Fig. 5.
Measured SPO2 percentage over time. : Ketamine and xylazine combined
anesthesia (K/X, 80/8 mg/kg). : Medetomidine, midazolam, and butorphanol combined
anesthesia with atipamezole (M/M/B, 0.3/4.0/5.0 mg/kg, atipamezole, 0.3 mg/kg). :
Pentobarbital sodium (50 mg/kg). : Isoflurane (induction,5%; maintenance, 2%). Data
are represented as means ± SD of 8 mice. There were significant differences between
the groups as follows: a, K/X and M/M/B groups; b, K/X and pentobarbital groups; and
e, M/M/B and isoflurane groups.
Measured respiratory rate (breaths/min) over time. : Ketamine and xylazine combined
anesthesia (K/X: 80/8 mg/kg). : Medetomidine, midazolam, and butorphanol combined
anesthesia with atipamezole (M/M/B: 0.3/4.0/5.0 mg/kg, atipamezole: 0.3 mg/kg). :
Pentobarbital sodium (50 mg/kg). : Isoflurane (induction,5%; maintenance, 2%). Data
are represented as means ± SD of 8 mice. There were significant differences between
the groups as follows: a, K/X and M/M/B groups; c, K/X and isoflurane groups; d, M/M/B
and pentobarbital groups; and e, M/M/B and isoflurane groups; and f, pentobarbital and
isoflurane groups.Measured SPO2 percentage over time. : Ketamine and xylazine combined
anesthesia (K/X, 80/8 mg/kg). : Medetomidine, midazolam, and butorphanol combined
anesthesia with atipamezole (M/M/B, 0.3/4.0/5.0 mg/kg, atipamezole, 0.3 mg/kg). :
Pentobarbital sodium (50 mg/kg). : Isoflurane (induction,5%; maintenance, 2%). Data
are represented as means ± SD of 8 mice. There were significant differences between
the groups as follows: a, K/X and M/M/B groups; b, K/X and pentobarbital groups; and
e, M/M/B and isoflurane groups.The mean ± SD of the CVs of each vital sign in each anesthetic group are shown in Fig. 6. Regarding the CV for rectal temperature, no significant differences were observed
among the groups (Fig. 6A). The K/X and M/M/B
groups showed higher variances in heart rate compared with the pentobarbital and isoflurane
groups (Fig. 6B). The CV of the respiratory rate
was significantly higher in the isoflurane group compared with other groups (Fig. 6C). In the MM/B group, the CV was significantly
higher than those of the K/X and isoflurane groups (Fig.
6D).
Fig. 6.
Instability in vital signs observed in each anesthetic group.
A: Rectal temperature. B: Heart rate. C: Respiratory rate. D: SPO2. Data
are represented as means ± SD of 8 mice.
Instability in vital signs observed in each anesthetic group.A: Rectal temperature. B: Heart rate. C: Respiratory rate. D: SPO2. Data
are represented as means ± SD of 8 mice.Finally, we evaluated the rates of mice achieving a surgical anesthetic depth in each
treatment group (Table 1). When anesthetized with pentobarbital, 62.5% of mice did not reach a surgical
anesthetic depth. In contrast, the remaining anesthetic protocols achieved a surgical
anesthetic depth at least once during the study period. The rate of mice reaching a surgical
anesthetic depth in the pentobarbital group was significantly lower than that in the other 3
groups (P<0.05).
Table 1.
Rate of achieving surgical anesthetic depth (%) for the four anesthetic protocols
performed on mice
Anesthetic protocol
Mice achieving surgical anesthesia (%)
K/X
100
M/M/B
100
Pentobarbital
37.5
Isoflurane
100
Discussion
The present study demonstrated the characteristics of three injectable anesthetics and one
inhalant anesthetic in mice, specifically the changes in vital signs. Each anesthetic
protocol showed different effects on cardiovascular and respiratory parameters.The vital signs were first evaluated in mice administered a mixture of ketamine and
xylazine. For surgical anesthesia in rodents, ketamine should be coadministered with a
sedative such as xylazine, acepromazine, or diazepam [4, 23]. Among these options, a combination
of ketamine and xylazine was selected because it is one of the most frequently used
anesthetic combinations in rodents [2, 4, 16]. Compared
with other agents, K/X provides a relatively stable respiratory rate and SPO2,
suggesting lessened respiratory depression. In contrast, the heart rate was relatively
unstable compared with the rates obtained with other injectable anesthetics such as
pentobarbital and M/M/B. The heart rate decrease was time dependent, and no recovery was
observed during the study period. A previous study demonstrated that the combination of
ketamine and xylazine mediates remarkable hypotension in mice [4]. Taken together, cardiovascular abnormality, rather than respiratory
depression, represents the major adverse reaction to K/X in mice. In the present study, the
doses of ketamine and xylazine were set to 100 and 10 mg/kg, respectively. Although the
cardiac influence was relatively strong, K/X at the present dose results in lower
respiratory depression and a sufficient anesthetic depth. The reported doses of K/X in mice
range from 60 to 150 mg/kg ketamine and 4.1 to 20 mg/kg xylazine [4]. As the required dose depends on the experimental conditions,
monitoring of vital signs under other doses may be important, along with evaluation of
anesthetic depth.The combination of midazolam, butorphanol, and medetomidine in rodent experimental
anesthesia is comparatively new [17, 18]. The efficacy of this anesthetic combination has also
been reported in dogs, sea lions, and monkeys [15,
25, 28].
Anesthesia with this combination is reversed with the α2-adrenergic antagonist atipamezole,
which antagonizes the medetomidine [28]. The present
study demonstrated the effect of M/M/B on the vital signs, as well as the reversal effect of
atipamezole. M/M/B anesthesia resulted in a marked decrease in heart rate. In dogs, the
heart rate markedly decreases when M/M/B is administered, while the blood pressure increases
[14]. A previous report in monkeys demonstrated
that M/M/B administration decreases the SPO2. Although the respiratory rate
variance was relatively stable in the present study, the SPO2 decrease was
marked, suggesting a lower tidal volume during M/M/B anesthesia. However, these abnormal
vital signs rapidly recovered following atipamezole administration. Therefore, the cardiac
and respiratory depression observed in mice seems to be mainly associated with the action of
medetomidine. Use of atipamezole will ensure the safety of M/M/B anesthesia in mice. We
clarified the features of M/M/B and the reversal action of atipamezole in mice, especially
its cardiorespiratory influence. Based on the present findings, comparison of M/M/B with
representative anesthetic protocols in other rodents may be warranted.It is said that pentobarbital monoanesthesia causes severe adverse cardiorespiratory
reactions and has poor analgesic action [9]. In the
present study, we adjusted the dosage of pentobarbital sodium to 50 mg/kg, which is a
relatively low dose in mice [10]. As a result, the
heart rate during pentobarbital anesthesia was higher than that during K/X. Stringent
comparison of the cardiovascular impacts during pentobarbital anesthesia and other
injectable anesthetics may be achieved by blood pressure evaluation. Regarding the
respiratory rate, there was no significant difference between K/X and pentobarbital
monoanesthesia. However, the SPO2 during pentobarbital monoanesthesia was lower
than that during K/X, indicating a lower tidal volume. Therefore, pentobarbital
monoanaesthesia at this dose resulted in higher respiratory depression than K/X. In the
present study, 62.5% of mice experienced an inadequate anesthetic depth under pentobarbital.
Similarly, in previous reports, administration of pentobarbital at 50 mg/kg did not induce
an adequate anesthetic depth in rodents [17, 23].Isoflurane is one of the most commonly used volatile anesthetics in laboratory rodents
[6]. The heart rate decrease with isoflurane was
lower than that observed in the injectable anesthetics, suggesting that isoflurane produces
the smallest cardiac influence. A recent study in rats also indicated that the pulse rate
under isoflurane anesthesia was higher than that under pentobarbital anesthesia [20]. However, compared with the injectable anesthetics,
isoflurane administration showed a prominent decrease in respiratory rate. Respiratory
depression is a major adverse effect of isoflurane [10]. Monitoring the respiratory rate is important when adjusting the gas
concentration to regulate the anesthetic depth. Notably, the SPO2 remained
relatively stable under isoflurane anesthesia. This result indicates that the blood
O2 concentration is maintained by a high tidal volume during isoflurane
anesthesia. A previous study also found that the hypercapnia associated with isoflurane was
less intense than that observed with the injectable anesthetic pentobarbital [26]. Additionally, isoflurane anesthesia showed a higher
SPO2 level than pentobarbital monoanesthesia in rats [20]. In the present study, the isoflurane concentration was set at 2% for
maintenance of anesthesia. The minimal alveolar concentration (MAC) is the concentration
that prevents reaction to a standard surgical stimulus in 50% of animals and is an index for
determining the inhalant anesthetic concentration [21]. Previous findings indicate that the MAC of isoflurane in many mouse strains is
approximately 1.3–1.4% [24]. Administering inhalant
anesthesia at 1.5 times the MAC is sufficient for surgical tolerance [6, 8]. Therefore, the isoflurane
concentration investigated in this study is assumed for surgical anesthesia in mice. Further
studies are warranted to determine the influence of isoflurane on vital signs across several
concentrations and flow rates and for a longer anesthetic period.In the present study, the closed colony strain ddY was used. Several factors, including
strain, sex, circadian rhythm, and metabolism can affect cardiovascular function under
anesthesia [7, 13, 27]. Evaluation of the vital signs
during various anesthetic protocols according to strain, age, and sex may be a concern in
the future. As operative stress alters cardiorespiratory function, assessment of vital signs
during surgical procedures with each anesthesia may also be required. A rodent pulse
oximeter was used to assess SPO2 as an indicator of respiratory function. The
pulse oximeter enables replicate measurement of the SPO2 over time during
anesthesia in mice without the need for any invasive procedures, while blood gas evaluation
can only assess the O2 concentration at a single point. The SPO2 is
routinely used to assess vital signs in human and veterinary medicine [3, 11]. Monitoring the
SPO2 is a valuable means of ensuring safe anesthesia in mice.Anesthetic agents affect systemic adverse reactions, which may affect experimental data.
Based on the present and previous studies, the combination of ketamine and xylazine has a
greater cardiac influence than other anesthetic agents [4]. However, the respiratory depression with this combination is less than that
observed with other protocols, suggesting that this combination is suitable for respiratory
experiments in mice. Among the four anesthetic protocols presently investigated, isoflurane
anesthesia may be preferable for hemodynamic analysis or anesthesia in a cardiac disorder
model. Although M/M/B anesthesia did influence cardiac and respiratory function, the use of
atipamezole ensures its safety. Along with isoflurane, M/M/B is appropriate in cases
requiring regulation of the duration of anesthesia. To definitively determine the
cardiorespiratory influence of these agents, assessment of other parameters such as blood
pressure, ETCO2, and electrocardiogram during anesthesia is warranted.In conclusion, we described the influence of several anesthetics on vital signs. The
findings of the present study provide basic information for achieving appropriate anesthesia
in mice and should contribute to improvement of laboratory animal welfare.
Authors: Brian D Hoit; Songsak Kiatchoosakun; Joseph Restivo; Darryl Kirkpatrick; Keith Olszens; Haifeng Shao; Yoh-Han Pao; Joseph H Nadeau Journal: Genomics Date: 2002-05 Impact factor: 5.736
Authors: Alysia A Chaves; Spencer J Dech; Tomohiro Nakayama; Robert L Hamlin; John Anthony Bauer; Cynthia A Carnes Journal: Life Sci Date: 2003-04-11 Impact factor: 5.037
Authors: Frederick W Damen; Amelia R Adelsperger; Katherine E Wilson; Craig J Goergen Journal: J Am Assoc Lab Anim Sci Date: 2015-11 Impact factor: 1.232
Authors: Kaitlyn T Bailey; Sanket R Jantre; Frank R Lawrence; F Claire Hankenson; Jacquelyn M Del Valle Journal: J Am Assoc Lab Anim Sci Date: 2022-08-31 Impact factor: 1.706
Authors: Ana Vaniqui; Brent van der Heyden; Isabel P Almeida; Lotte Ejr Schyns; Stefan J van Hoof; Frank Verhaegen Journal: Br J Radiol Date: 2018-07-20 Impact factor: 3.039
Authors: Rachael M Zemek; Vanessa S Fear; Cath Forbes; Emma de Jong; Thomas H Casey; Louis Boon; Timo Lassmann; Anthony Bosco; Michael J Millward; Anna K Nowak; Richard A Lake; W Joost Lesterhuis Journal: Nat Protoc Date: 2020-04-01 Impact factor: 13.491
Authors: Alessandro Venturino; Rouven Schulz; Héctor De Jesús-Cortés; Margaret E Maes; Bálint Nagy; Francis Reilly-Andújar; Gloria Colombo; Ryan John A Cubero; Florianne E Schoot Uiterkamp; Mark F Bear; Sandra Siegert Journal: Cell Rep Date: 2021-07-06 Impact factor: 9.995
Authors: Kaela L Navarro; Monika Huss; Jennifer C Smith; Patrick Sharp; James O Marx; Cholawat Pacharinsak Journal: ILAR J Date: 2021-12-31 Impact factor: 1.521